CELC Celcuity Inc.

CIK 0001603454 50 ready 8-Ks latest June 8, 2026, 4:10 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing June 8, 2026, 4:10 PM ET

Top materiality 0.95

Event mix other_material ×23 · earnings ×14 · debt ×5

Sentiment 16 pos · 1 neg · 33 neu

Latest earnings reported 2025-Q3

Executive change recent →

Recent 8-K filings for CELC

Highest-materiality recent filing

Celcuity Phase 3 VIKTORIA-1 PIK3CA wild-type: gedatolisib triplet cuts progression/death risk by 76% (HR 0.24)

July 28, 2025, 7:59 PM ET other material materiality 0.95 positive item 7.01 item 8.01 item 9.01

Gedatolisib triplet (plus palbociclib/fulvestrant) mPFS 9.3 mo vs 2.0 mo for fulvestrant, incremental gain 7.3 mo.
Gedatolisib doublet (plus fulvestrant) mPFS 7.4 mo vs 2.0 mo, reducing risk by 67% (HR 0.33; p<0.0001).

Read filing →

June 8, 2026, 4:10 PM ET debt materiality 0.70 neutral item 1.01 item 1.02 item 2.03 item 8.01 item 9.01 ◈ Debt Financings◈ Material Agreements

Celcuity closes $575M convertible note offering at 0.250% due 2032, repays $137.5M loan

Issued $575M aggregate principal of 0.250% Convertible Senior Notes due 2032; net proceeds ~$557M.
June 2, 2026, 8:10 AM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Gedatolisib doubles PFS vs alpelisib in PIK3CA mutant HR+/HER2- ABC Phase 3 trial

Gedatolisib-triplet reduced risk of progression or death by 50% (HR=0.50; p<0.0001); median PFS 11.1 vs 5.6 months.
May 14, 2026, 4:05 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

Celcuity reports Q1 net loss $52.8M; VIKTORIA-1 hits primary endpoint in PIK3CA mutant

Net loss $52.8M ($0.97/share) vs $37.0M ($0.86/share) in Q1 2025; non-GAAP adjusted net loss $46.8M ($0.86).
May 1, 2026, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Celcuity Phase 3 VIKTORIA-1 PIK3CA mutant cohort meets primary endpoint with significant PFS improvement

Gedatolisib triplet (plus fulvestrant and palbociclib) showed statistically significant PFS improvement vs alpelisib+fulvestrant.
March 25, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

Celcuity reports Q4 loss $0.97/share; FDA grants Priority Review for gedatolisib, PDUFA July 17, 2026

Net loss Q4 $51.0M ($0.97), FY $177.0M ($3.79); adjusted net loss Q4 $38.4M ($0.73), FY $150.8M ($3.22).
November 17, 2025, 6:59 PM ET regulatory materiality 0.90 positive item 7.01 item 8.01 item 9.01

Celcuity completes NDA submission to FDA for gedatolisib in HR+/HER2- advanced breast cancer under RTOR program

NDA submitted for gedatolisib in HR+/HER2-, PIK3CA wild-type advanced breast cancer.
November 12, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Celcuity Q3 net loss $43.8M; gedatolisib NDA on track for Q4 2025

Q3 net loss $43.8M ($0.92 loss per share) vs $29.8M ($0.70 loss) in prior year.
October 20, 2025, 7:59 PM ET other material materiality 0.90 positive item 7.01 item 8.01 item 9.01

Phase 3 VIKTORIA-1 data: gedatolisib triplet reduces progression risk by 76% in HR+/HER2- ABC

Median PFS 9.3mo for gedatolisib triplet vs 2.0mo for fulvestrant (HR=0.24); incremental 7.3mo improvement.
September 10, 2025, 7:59 PM ET debt materiality 0.85 positive item 1.01 item 2.03 item 3.02 item 7.01 item 9.01 ◈ Debt Financings ×5◈ Equity Issuances

Celcuity upsizes senior secured facility to $500M, receives $30M immediate funding

Total facility increased to $500M ($350M committed + $150M discretionary); $30M funded, total outstanding $130M.
August 14, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Celcuity reports Phase 3 gedatolisib milestone; NDA filing on track for Q4 2025

Phase 3 VIKTORIA-1: gedatolisib triplet reduced risk of progression/death by 76% (HR=0.24); median PFS 9.3 mo vs 2.0 mo.
August 1, 2025, 7:59 PM ET debt materiality 0.75 neutral item 1.01 item 2.03 item 8.01 item 9.01 ◈ Debt Financings

Celcuity issues $201.25M of 2.750% convertible notes due 2031; net proceeds ~$194.5M

Issued $201.25M aggregate principal of 2.750% Convertible Senior Notes due 2031; initial conversion price ~$51.30/share.
July 31, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 8.01 item 9.01

Celcuity prices $175M convertible notes and stock offering; net proceeds ~$248.7M

$175M of 2.750% convertible senior notes due 2031 priced; initial conversion price ~$51.30/share (35% premium to stock offering).
July 29, 2025, 7:59 PM ET other material materiality 0.85 neutral item 1.01 item 8.01 item 9.01

Celcuity launches $150M convertible notes + $75M common stock offerings; also to draw $30M loan

Concurrent underwritten offerings: $150M convertible notes due 2031 and $75M common stock; 30-day over-allotment options for additional $22.5M notes and $11.25M stock.
July 28, 2025, 7:59 PM ET other material materiality 0.95 positive item 7.01 item 8.01 item 9.01

Celcuity Phase 3 VIKTORIA-1 PIK3CA wild-type: gedatolisib triplet cuts progression/death risk by 76% (HR 0.24)

Gedatolisib triplet (plus palbociclib/fulvestrant) mPFS 9.3 mo vs 2.0 mo for fulvestrant, incremental gain 7.3 mo.
June 30, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Celcuity reports 66% six-month rPFS in mCRPC Phase 1, 43% ORR in HER2+ mBC Phase 2

Phase 1 mCRPC (gedatolisib + darolutamide): 66% six-month rPFS; no treatment-related discontinuations or Grade 3 hyperglycemia; Grade 2-3 stomatitis in 10.5% of patients.
March 31, 2025, 7:59 PM ET other material materiality 0.72 negative item 2.02 item 9.01

Celcuity posts Q4 net loss $36.7M, cash $235M, key trial data anticipated in 2025

Q4 net loss $36.7M ($0.85/share) vs $18.8M ($0.65/share) in Q4 2023; full year net loss $111.8M ($2.83/share).
December 6, 2024, 6:59 PM ET other material materiality 0.65 neutral item 8.01 item 9.01

Celcuity establishes new $125M at-the-market equity offering program

New ATM facility with Jefferies allows up to $125M additional common stock sales.
November 14, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Celcuity Q3 net loss $29.8M ($0.70/sh); VIKTORIA-1 wild-type cohort 100% enrolled

PIK3CA wild-type cohort of VIKTORIA-1 100% enrolled; topline data expected late Q1 2025 or Q2 2025.
August 14, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Celcuity Q2 net loss widens to $23.7M; VIKTORIA-1 PIK3CA WT cohort enrollment delayed to Q4 2024

Net loss of $23.7M ($0.62/share) vs $14.6M ($0.66/share) YoY; non-GAAP adjusted loss per share $0.58.
May 31, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 8.01 item 9.01

Celcuity prices $60M common stock offering of 3.871M shares at $15.50

3,871,000 shares priced at $15.50 per share; gross proceeds $60.0M, net ~$56.2M.
May 30, 2024, 7:59 PM ET other material materiality 0.80 positive item 1.01 item 8.01 item 2.03 item 3.02 item 9.01

Celcuity secures up to $180M debt financing, plans Phase 3 gedatolisib trial in HR+/HER2- breast cancer

New A&R Loan Agreement with Innovatus and Oxford provides up to $180M; $100M funded including $61.7M new borrowings.
May 15, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Celcuity Q1 net loss $21.6M; Phase 3 VIKTORIA-1 on track for H2 2024 data

Net loss $21.6M ($0.64/sh) vs $11.9M ($0.55/sh) in Q1 2023; cash $177.7M expected runway into H1 2026.
March 27, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Celcuity Q4 net loss $18.8M; FY net loss $63.8M; cash into H1 2026; VIKTORIA-1 topline data H2 2024

Net loss Q4 2023 $18.8M ($0.65 loss per share) vs $11.6M ($0.69) in Q4 2022.
November 13, 2023, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Celcuity Q3 net loss $18.4M; raises $50M; advances gedatolisib in prostate cancer

Q3 net loss $18.4M ($0.83 loss per share) vs $10.9M ($0.75) YoY; non-GAAP adjusted loss $17.3M ($0.78).
October 23, 2023, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.02 item 8.01 item 9.01 ◈ Material Agreements ×2

Celcuity raises $50M via private placement of pre-funded warrants

Gross proceeds of ~$50M from sale of pre-funded warrants to institutional investor.
August 24, 2023, 7:59 PM ET other material materiality 0.60 neutral item 5.02

Celcuity adjusts executive compensation; CEO base salary down, CFO base up ~22% with stock options

CEO base salary decreased slightly; CSO base up <10%; CFO base up ~22% partially paid in stock options.
August 22, 2023, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Celcuity to start Phase 1b/2 trial of gedatolisib + darolutamide in mCRPC; Bayer supplies drug free

FDA cleared IND for gedatolisib in combination with darolutamide; trial to begin Q1 2024.
August 10, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Celcuity Q2 net loss $14.6M; Phase 1b gedatolisib data shows 48.6-month median PFS

Net loss $14.6M ($0.66/share) vs $10.0M ($0.67) Q2 2022; non-GAAP adjusted net loss $12.8M.
May 15, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Celcuity Q1 2023 net loss $11.9M; Phase 1b gedatolisib shows median PFS 48.6 months

Net loss of $11.9M ($0.55 loss per share) vs $7.9M ($0.53 loss per share) in Q1 2022.
December 23, 2022, 6:59 PM ET debt materiality 0.60 neutral item 2.03 ◈ Debt Financings

Celcuity closes $20M term loan from Innovatus under existing credit facility

Closed $20.0M Term B Loan on Dec 22, 2022; part of previously disclosed $75M facility.
November 10, 2022, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Celcuity Q3 net loss $10.9M ($0.75/sh); Phase 3 VIKTORIA-1 site activation underway

Net loss $10.9M ($0.75/sh) vs $6.0M ($0.41/sh) in Q3 2021; adjusted net loss $9.5M ($0.63/sh).
September 14, 2022, 7:59 PM ET leadership materiality 0.60 positive item 1.01 item 3.03 item 5.02 item 9.01 ◈ executive_change

Celcuity appoints Dr. Polly Murphy to Board; reduces warrant shares to 70K

Warrant amended: shares reduced from 138,000 to 70,000; exercise period extended to Sept 19, 2025.
August 11, 2022, 7:59 PM ET other material materiality 0.80 positive item 1.01 item 2.02 item 2.03 item 9.01

Celcuity expands debt to $75M, Q2 net loss $10M, gedatolisib gets Breakthrough Therapy

Debt facility amended to up to $75M ($50M increase); $15M drawn, $20M due on private placement close; other tranches tied to clinical milestones.
May 19, 2022, 7:59 PM ET other material materiality 0.60 neutral item 5.02

Celcuity grants stock options to execs in lieu of salary, reprices outstanding options to $5.50

CEO Brian Sullivan granted options for 250,000 shares in lieu of 14-month base salary starting June 1, 2022.

Executive changes

Appointed

Charles (Chip) R. Romp

Director

CELC · Celcuity Inc.

Effective: 2026-02-11
Filed: May 20, 2026, 7:30 AM ET

On February 11, 2026, the Board of Directors (the “Board”) of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “N&CG Committee”), voted to increase the size of the Board from seven members to eight members and to appoint Charles (Chip) R. Romp as a new director to fill the resulting vacancy, effective immediately, for a term extending through the date of the Company’s 2026 Annual Meeting of Stockholders and the election of his successor, or his earlier death, resignation or removal.

Appointed

Polly Murphy

Director

CELC · Celcuity Inc.

Effective: 2022-09-12
Filed: September 14, 2022, 7:59 PM ET

On September 12, 2022, the Board of Directors (the “Board”) of the Company, voted to increase the size of the Board from six members to seven members and to elect Polly Murphy, D.V.M., Ph.D. as a new director to fill the resulting vacancy.

Earnings & guidance

2025-Q3 EPS reported -$2.81 filing →

Materiality & sentiment trend

Max materiality 0.95 · Median 0.65 · Most common event other_material

16 positive 1 negative 33 neutral

source · CELC on sec.gov